3D organoids derived from a patient’s own cells are able to reproduce some key properties of the primary tissue. Therefore, organoids’ responses to drugs and therapies are closer to actual in vivo responses than other systems.It is because of these advantages that tumor organoids are now applied in a variety of scenarios. First, they can be used for high-throughput drug screening. By culturing a patient’s tumor organoids and screening them for drugs, it is possible to determine the appropriate drugs for the patient and precisely treat their disease. Tumor organoids can also be used for rapid tumor type screening. After the establishment of banks of various subtypes of tumor organoids, by culturing a patient’s tumor organoids and examining their morphology, gene expression profiles, and drug response, we can rapidly classify the tumor and predict the patient’s prognosis.